Bacterial Infections  >>  Pneumovax 23 (23-valent pneumococcal polysaccharide)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
NCT01513551 / 2011-004542-18: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Completed
2
692
NA
Pneumococcal Conjugate Vaccine (V114), PNEUMOVAX® 23, PREVNAR 13®
Merck Sharp & Dohme LLC
Pneumococcal Infections
02/13
02/13
NCT00137605: Early Versus Delayed Pneumococcal Vaccination in HIV

Completed
1/2
79
Canada
Pneumovax, Prevnar
CIHR Canadian HIV Trials Network, Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections
 
10/07

Download Options